56 completed, 4 terminated, 1 withdrawn. 61 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 61 | Completed 56, Terminated 4, Withdrawn 1 |
Follow Duration of Therapy: new trials by email Literature Review of Duration of Therapy trials Research Report on Duration of Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of MK0524A on Flushing Caused by Niacin (0524A-056) MK0524A, /Duration of Treatment : 4 Weeks, Comparator : niacin /Duration of Treatment : 1 Weeks - Flushing | Phase 3 | Completed | Merck Sharp & Dohme LLC | 330 | 2007-04-01 | 2017-02-17 |
| Adult Polysomnography Primary Insomnia Cross Over Study (0928-049)(TERMINATED) MK0928 / Duration of Treatment : 8 Weeks - Primary Insomnia | Phase 3 | Terminated | H. Lundbeck A/S | 138 | 2006-09-01 | 2015-01-14 |
| Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122) MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks, Comparator: atorvastatin / Duration of Treatment: 6 Weeks - Cardiovascular Diseases, Diabetes Mellitus | Phase 3 | Terminated | Organon and Co | 550 | 2006-09-01 | 2024-08-15 |
| Effectiveness of Smecta in Combination With Oral Rehydration in the Treatment of Acute Watery Diarrhoea in Infants and Children Smecta (Diosmectite), duration of treatment - 7 days - Diarrhoea | Phase 3 | Completed | Ipsen | 302 | 2006-07-01 | 2019-11-22 |
| Effectiveness of Smecta in the Treatment of Acute Diarrhoea in Children Smecta (Diosmectite), duration of treatment - 7 days - Diarrhoea | Phase 3 | Completed | Ipsen | 300 | 2006-06-01 | 2019-11-22 |
| An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325) MK0954, losartan potassium / Duration of Treatment - 12 weeks - Hypertension | Phase 3 | Terminated | Organon and Co | 11 | 2006-03-13 | 2024-08-15 |
| Evaluate the Safety and Efficacy of Caspofungin Acetate as Empirical Therapy in Chinese Adults With Persistent Fever and Neutropenia (0991-055) MK0991, caspofungin acetate / Duration of Treatment: - Fungal Infection | Phase 3 | Completed | Merck Sharp & Dohme LLC | 131 | 2006-03-01 | 2015-12-17 |
| Upper GI Handling of Branded vs. Generic Alendronate MK0217, alendronate sodium / Duration of Treatment: 1 Month, Comparator: Alendronate-Teva / Duration of Treatment: 1 Month - Osteoporosis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 25 | 2005-12-01 | 2006-11-17 |
| SINGULAIR (R) as Complementary Therapy to Fixed Association Regimen (0476-363) MK0476, montelukast sodium / Duration of Treatment: 8 Weeks - Asthma | Phase 3 | Completed | Organon and Co | 198 | 2005-11-01 | 2024-08-15 |
| Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323) MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks - Hypertension | Phase 3 | Completed | Organon and Co | 62 | 2005-09-01 | 2024-08-15 |
| To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366) MK0476, montelukast sodium / Duration of Treatment: 12 Weeks - Asthma | Phase 3 | Completed | Organon and Co | 58 | 2005-08-01 | 2024-08-15 |
| To Evaluate the Treatment Effect of an Anti-Infective Agent for Different Kinds of Infections (0826-052) MK0826, ertapenem sodium / Duration of Treatment: 14 Days - Infection, Pneumonia | Phase 3 | Completed | Merck Sharp & Dohme LLC | 30 | 2005-07-01 | 2017-02-17 |
| Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071) MK0462, rizatriptan benzoate / Duration of Treatment -1 day, Comparator: placebo / Duration of Treatment - 1 day - Migraine | Phase 3 | Completed | Organon and Co | 393 | 2005-05-27 | 2024-08-14 |
| Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072) MK0462, rizatriptan benzoate / Duration of Treatment -1day, Comparator: placebo / Duration of Treatment - 1 day - Migraine | Phase 3 | Completed | Organon and Co | 393 | 2005-05-27 | 2024-08-14 |
| Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070) MK0653, ezetimibe / Duration of Treatment: 4 Weeks - Hypercholesterolemia | Phase 3 | Completed | Organon and Co | 440 | 2005-04-01 | 2024-08-15 |
| Ezetimibe Added to Statin Therapy (EASY) Study (0653-087)(COMPLETED) MK0653, ezetimibe / Duration of Treatment: 6 Weeks - Hypercholesterolemia | Phase 3 | Completed | Organon and Co | 141 | 2005-03-01 | 2024-05-10 |
| Eze/Simva Switch Study in Diabetics (0653A-807) MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks, Comparator: atorvastatin / Duration of Treatment: 6 Weeks - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Organon and Co | 648 | 2005-01-19 | 2024-08-15 |
| Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval - Acromegaly | Phase 3 | Completed | Ipsen | 38 | 2005-01-01 | 2019-11-22 |
| An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007) MK0928, gaboxadol / Duration of Treatment: 10 months - Insomnia | Phase 3 | Withdrawn | H. Lundbeck A/S | 2005-01-01 | 2015-01-14 | |
| MK0954A-264 Filter Study (0954A-264)(COMPLETED) MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks, losartan / Duration of Treatment: 6 weeks - Mild to Severe Hypertension | Phase 3 | Completed | Organon and Co | 274 | 2004-12-01 | 2024-08-15 |
Showing 20 of 61. Sign in to see all of them.
Hypercholesterolemia (6) · Hypertension (5) · Asthma (4) · Migraine Disorders (4) · Osteoporosis (4) · Osteoporosis, Postmenopausal (4) · Sleep Initiation and Maintenance Disorders (4) · Diabetes Mellitus, Type 2 (3) · Acromegaly (2) · Condylomata Acuminata (2) · Coronary Disease (2) · Diarrhea (2) · Low Back Pain (2) · Osteoarthritis (2) · Uterine Cervical Neoplasms (2)
Organon and Co (38) · Merck Sharp & Dohme LLC (15) · H. Lundbeck A/S (4) · Ipsen (4)
Germany (1) · Italy (1) · Malaysia (1) · Peru (1)
PMID 16291062, PMID 17196507, PMID 17502347, PMID 17985033, PMID 18922570, PMID 19059567, PMID 19236277, PMID 19236279, PMID 19332468, PMID 19487264, PMID 19505910, PMID 19542735, PMID 20001655, PMID 20191935, PMID 20200926, PMID 20589977, PMID 20601389, PMID 21086246, PMID 21239405, PMID 21300618, PMID 21304095, PMID 21307649, PMID 21358415, PMID 21720264, PMID 22243363, PMID 22695506, PMID 22753219, PMID 23062719, PMID 23403268, PMID 24379001, PMID 24723582, PMID 24798675, PMID 25340854, PMID 26056336, PMID 26089332, PMID 26378687, PMID 29151037, PMID 29176391, PMID 29474712, PMID 29580174, PMID 30676480, PMID 31926466, PMID 32184277, PMID 32586143, PMID 32586346, PMID 35213289, PMID 35345262, PMID 35525430
2004 (1)